Search clinical trials for: T-1101+%28Tosylate%29

Total 140 results

Taivex Therapeutics Corporation

Terminated

Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Taivex Therapeutics Corporation

Active, not recruiting

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Taivex Therapeutics Corporation

Completed

An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors

Taiwan
Taivex Therapeutics Corporation

Recruiting

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Lymphoma | Advanced Solid Tumor

Taiwan
Lingli Dong
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Lupus Nephritis | ANCA Associated Vasculitis

China
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Poseida Therapeutics, Inc.

Active, not recruiting

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Metastatic Castration-resistant Prostate Cancer | Neoplasms... and other conditions

United States
Poseida Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Verismo Therapeutics

Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma Recurrent

United States
Taivex Therapeutics Corporation

Recruiting

Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Taiwan
Chimeric Therapeutics

Not yet recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors
Ottawa Hospital Research Institute

Recruiting

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent... and other conditions

United States
Daiichi Sankyo

Recruiting

A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors

Advanced Solid Tumor

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
gicare Pharma Inc.
Algorithme Pharma Inc

Completed

Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method

Pain | Cancer | Colonic Disease

Canada
Turnstone Biologics, Corp.

Recruiting

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING)

Breast Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Uveal Melanoma | Cutaneous Melanoma

United States, Canada
Queensland Institute of Medical Research
Merck Sharp & Dohme LLC; Royal Brisbane and Women's Hospital; Princess Alexandra... and other collaborators

Recruiting

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP)

Glioblastoma Multiforme | Astrocytoma, Grade IV

Australia
Stanford University
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive

United States
HRYZ Biotech Co.

Recruiting

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Cervical Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | Anal Carcinoma | Vagina Tumor | Carcinoma of Penis | Carcinoma of Vulva

China
TCR2 Therapeutics

Completed

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Kidney Medullary Carcinoma | Loss of INI 1 Protein Expression

United States
Mie University
Fiverings Co., Ltd.; Shionogi; Takara Bio Inc.; Statcom Co. Ltd.

Completed

Investigator Initiated Phase 1 Study of TBI-1201

Solid Tumors

Japan
Mie University
Fiverings Co., Ltd.; Shionogi; Takara Bio Inc.; Statcom Co. Ltd.

Unknown

Investigator Initiated Phase 1 Study of TBI-1301

Solid Tumors

Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Recurrent Glioblastoma | Refractory Glioblastoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Hepatocellular Carcinoma | Resectable Hepatocellular Carcinoma

United States
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3)

Lupus Nephritis | Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class III

Germany
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Lupus Nephritis | Lupus Nephritis - World Health Organization (WHO) Class III | Lupus Nephritis - WHO Class IV

United States
Radboud University Medical Center
AstraZeneca

Completed

Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer (Donan)

Non-small Cell Lung Cancer

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (STARVE-PC)

Prostate Cancer | Recurrent Prostate Carcinoma | Stage IV Prostate Adenocarcinoma

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Major Salivary Gland Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Carcinoma | Stage IVB Major Salivary Gland Carcinoma | Stage IVC Major Salivary Gland Carcinoma | Minor Salivary Gland Carcinoma | Stage IV Major Salivary Gland Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery

Gastrointestinal Stromal Tumor

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Stage IV Breast Cancer | HER2/Neu Negative | Recurrent Inflammatory Breast Carcinoma | Stage IV Inflammatory Breast Carcinoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Fondazione Italiana Linfomi - ETS
Janssen-Cilag S.p.A.

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (FIL_DALYA)

Plasmablastic Lymphoma

Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Advanced Colon Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Recurrent Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell Myeloma | Myeloproliferative Neoplasm | Recurrent... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Dedifferentiated Liposarcoma | Resectable Dedifferentiated Liposarcoma | Resectable Undifferentiated Pleomorphic Sarcoma | Recurrent Dedifferentiated Liposarcoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
National Cancer Institute (NCI)

Withdrawn

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Hematopoietic and Lymphoid Cell Neoplasm | Lynch Syndrome | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central... and other conditions

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Malignant Peritoneal Neoplasm | Recurrent Endometrial Carcinoma | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Metastatic Malignant Female... and other conditions

United States
Claire Verschraegen

Completed

Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

Merkel Cell Carcinoma | Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8

United States

Search clinical trials for: T-1101+%28Tosylate%29

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations